Anders Svenningsson

Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies

Gustavo Luna, Peter Alping, Joachim Burman et al. · JAMA Neurology · 2019 · 492 citations · Full text

Monitoring disease activity in multiple sclerosis using serum neurofilament light protein

Lenka Novakova, Henrik Zetterberg, Peter Sundström et al. · Neurology · 2017 · 409 citations · Full text

Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study

Anna He, B. Merkel, J William L Brown et al. · The Lancet Neurology · 2020 · 401 citations · Full text

Disease Progression, Neurological Disorder, Clinical Epidemiology +7

Rituximab in multiple sclerosis

Jonatan Salzer, Rasmus Svenningsson, Peter Alping et al. · Neurology · 2016 · 340 citations · Full text

Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab

Martin Gunnarsson, Clas Malmeström, Markus Axelsson et al. · Annals of Neurology · 2010 · 337 citations · Full text